Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:LTUS NASDAQ:PLRX NASDAQ:XBIT NYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTUSLotus Pharmaceuticals$0.01-38.8%$0.01$0.00▼$0.01$13.75M-2.3414,911 shs246,000 shsPLRXPliant Therapeutics$1.86+14.1%$1.51$1.10▼$16.10$114.18M1.43996,381 shs3.43 million shsXBITXBiotech$2.92-2.0%$3.04$2.50▼$8.32$89.02M0.8546,330 shs30,295 shsZOMZomedica$0.12$0.09▼$0.16$95.35M1.034.72 million shs790,936 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTUSLotus Pharmaceuticals0.00%-38.82%-3.70%+4.00%+79.31%PLRXPliant Therapeutics0.00%+13.41%+10.71%+14.11%-85.49%XBITXBiotech0.00%-7.59%0.00%+0.69%-48.95%ZOMZomedica0.00%0.00%0.00%0.00%-24.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTUSLotus Pharmaceuticals$0.01-38.8%$0.01$0.00▼$0.01$13.75M-2.3414,911 shs246,000 shsPLRXPliant Therapeutics$1.86+14.1%$1.51$1.10▼$16.10$114.18M1.43996,381 shs3.43 million shsXBITXBiotech$2.92-2.0%$3.04$2.50▼$8.32$89.02M0.8546,330 shs30,295 shsZOMZomedica$0.12$0.09▼$0.16$95.35M1.034.72 million shs790,936 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTUSLotus Pharmaceuticals0.00%-38.82%-3.70%+4.00%+79.31%PLRXPliant Therapeutics0.00%+13.41%+10.71%+14.11%-85.49%XBITXBiotech0.00%-7.59%0.00%+0.69%-48.95%ZOMZomedica0.00%0.00%0.00%0.00%-24.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLTUSLotus Pharmaceuticals 0.00N/AN/AN/APLRXPliant Therapeutics 2.08Hold$8.19340.19% UpsideXBITXBiotech 0.00N/AN/AN/AZOMZomedica 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest LTUS, XBIT, PLRX, and ZOM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/10/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/8/2025PLRXPliant TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$17.00 ➝ $4.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/APLRXPliant Therapeutics$1.58M72.27N/AN/A$5.00 per share0.37XBITXBiotech$4.01M22.20N/AN/A$5.98 per share0.49ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/APLRXPliant Therapeutics-$210.30M-$3.40N/AN/AN/AN/A-73.45%-55.66%11/6/2025 (Estimated)XBITXBiotech-$38.53M-$0.92N/A∞N/AN/A-15.60%-14.64%11/11/2025 (Estimated)ZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest LTUS, XBIT, PLRX, and ZOM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XBITXBiotechN/A-$0.06N/A-$0.06N/AN/A8/7/2025Q2 2025PLRXPliant Therapeutics-$0.62-$0.71-$0.09-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLTUSLotus PharmaceuticalsN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLTUSLotus PharmaceuticalsN/AN/AN/APLRXPliant Therapeutics0.1412.9912.99XBITXBiotechN/A40.1640.16ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLTUSLotus PharmaceuticalsN/APLRXPliant Therapeutics97.30%XBITXBiotech55.70%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipLTUSLotus PharmaceuticalsN/APLRXPliant Therapeutics6.40%XBITXBiotech30.80%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionablePLRXPliant Therapeutics9061.39 million57.46 millionOptionableXBITXBiotech10030.49 million21.10 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableLTUS, XBIT, PLRX, and ZOM HeadlinesRecent News About These CompaniesZomedica Corp.: Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent PracticesAugust 19, 2025 | finanznachrichten.deZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary MedicineAugust 12, 2025 | finanznachrichten.deZomedica Achieves Record Revenue Growth in Q2 2025August 6, 2025 | msn.comNon-Pharmacologic Solutions for Pet Dental Health From Prevention to RecoveryJuly 11, 2025 | dvm360.comDZomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - OcalaJuly 10, 2025 | finanznachrichten.deZomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - MorningstarJune 25, 2025 | morningstar.comMZomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 20, 2025 | finanznachrichten.deTreat pet pain, inflammation, and anxiety with this high-tech at home therapyApril 24, 2025 | click2houston.comCHelping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family MembersApril 11, 2025 | pix11.comPIs Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.com15 Cheapest Stocks Insiders Are Buying In MarchMarch 27, 2025 | insidermonkey.comEarnings call transcript: Zomedica Q4 2024 shows revenue growthMarch 15, 2025 | investing.comQ4 2024 Zomedica Corp Earnings CallMarch 15, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comZomedica (ZOMDF) Gets a Buy from Noble FinancialMarch 11, 2025 | markets.businessinsider.comZomedica Corp.March 8, 2025 | wsj.comZomedica Corp. Announces Transition to OTCQB Venture MarketMarch 4, 2025 | accessnewswire.comANYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)March 4, 2025 | businesswire.comZomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ETFebruary 26, 2025 | accessnewswire.comAZomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New HeadquartersFebruary 12, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTUS, XBIT, PLRX, and ZOM Company DescriptionsLotus Pharmaceuticals OTCMKTS:LTUS$0.0052 0.00 (-38.82%) As of 09/5/2025 12:45 PM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Pliant Therapeutics NASDAQ:PLRX$1.86 +0.23 (+14.11%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.81 -0.05 (-2.69%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.XBiotech NASDAQ:XBIT$2.92 -0.06 (-2.01%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.92 0.00 (0.00%) As of 09/5/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
